MCI is an intermediate stage that is often, but not always, a transitional phase between normal age-related cognitive decline and dementia ( Anderson, 2019). This neurodegenerative disease is clinically characterized by a gradual decline in cognitive ability, which is in part due to the presence of neuritic beta-amyloid plaques and neurofibrillary tau protein tangles ( Murphy and LeVine, 2010).Īnother condition characterized by neurocognitive decline is Mild Cognitive Impairment (MCI). Accounting for 60-80% of all dementia cases is Alzheimer’s Disease (AD) ( Alzheimer’s Association, 2020), a progressive brain disorder that is a major global healthcare burden. With this, the prevalence of dementia is also expected to significantly increase ( Norton, Matthews and Brayne, 2013). Subscribe to Morningstar Investor today.The proportion of the world’s elderly population (age over 60 years) is projected to increase to 22% by 2050 (almost double the proportion in 2015) ( Kanasi, Ayilavarapu and Jones, 2016). To learn more about MoCA Cognition, visit View original content to download multimedia: Įvaluate the market like an analyst. Our mission is fueled by our passionate belief that everyone deserves a memorable life. Nasreddine leads MoCA Cognition, a research and innovation-focused company driven to deliver the next generation of cognitive screening solutions. 2023).Īlong with his continued dedication to patients at his high-volume memory clinic, Dr. Ziad Nasreddine was recently ranked number 1 among 53 cognitive screening tests for early detection of Alzheimer's Disease (Outcome Measures for Alzheimer's Disease: A global inter-societal Delphi consensus. The Montreal Cognitive Assessment, or MoCA Test, created by Dr. Visit learn more information about the XpressO by MoCA. Nasreddine, neurologist and MoCA Cognition CEO. XpressO was conceived to provide peace of mind to the 'worried well' and motivation to consult with a physician for others," explained Dr. Demand for cognitive testing is growing, both among seniors with normal brain health and with impairment. "Early detection permits earlier intervention that saves major healthcare costs and improves patient outcomes. Notably, recent FDA-approved Alzheimer's treatments specifically require early diagnosis of a patient, still in the MCI range, for eligibility. Validation studies have demonstrated an approximately 85% accuracy in predicting a MoCA score in the mild cognitive impairment (MCI) range. This is particularly important considering our aging population, limited public care resources, and new Alzheimer's Disease treatments coming available. The XpressO by MoCA app was developed in response to growing needs of primary care to detect cognitive impairment, quickly and accurately. 21, 2024 /PRNewswire/ - MoCA Cognition, the company behind the world's leading test for early detection of cognitive impairment-the Montreal Cognitive Assessment or MoCA Test-is announcing the US public release of its new "XpressO by MoCA" self-assessment app for the general population.įor the public concerned with their cognitive performance, or that of a loved one, MoCA Cognition offers the scientifically validated "XpressO by MoCA" app-a rapid cognitive self-assessment tool that can predict performance on the MoCA Test and suggest when to consult with a healthcare professional. POTUS Cognitive Test Creators Introduce MoCA-XpressO for Public Use
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |